Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Plus Therapeutics (PSTV) Net Income towards Common Stockholders (2016 - 2025)

Plus Therapeutics has reported Net Income towards Common Stockholders over the past 15 years, most recently at -$5.7 million for Q4 2025.

  • Quarterly Net Income towards Common Stockholders fell 46.37% to -$5.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$15.7 million through Dec 2025, down 7.73% year-over-year, with the annual reading at -$15.7 million for FY2025, 7.73% down from the prior year.
  • Net Income towards Common Stockholders was -$5.7 million for Q4 2025 at Plus Therapeutics, down from -$4.4 million in the prior quarter.
  • Over five years, Net Income towards Common Stockholders peaked at -$1.5 million in Q2 2023 and troughed at -$5.7 million in Q4 2025.
  • The 5-year median for Net Income towards Common Stockholders is -$3.8 million (2023), against an average of -$3.8 million.
  • Year-over-year, Net Income towards Common Stockholders soared 72.04% in 2023 and then plummeted 146.76% in 2024.
  • A 5-year view of Net Income towards Common Stockholders shows it stood at -$3.7 million in 2021, then tumbled by 50.56% to -$5.6 million in 2022, then skyrocketed by 32.09% to -$3.8 million in 2023, then fell by 2.44% to -$3.9 million in 2024, then plummeted by 46.37% to -$5.7 million in 2025.
  • Per Business Quant, the three most recent readings for PSTV's Net Income towards Common Stockholders are -$5.7 million (Q4 2025), -$4.4 million (Q3 2025), and -$1.5 million (Q2 2025).